Every S-3 that Aprea Therapeutics, Inc. (APRE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow APRE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APRE filings page.
Aprea Therapeutics, Inc. has filed a shelf registration on Form S-3 to register 74,349,426 shares of Common Stock for resale by selling stockholders. The shares represent up to 37,174,713 shares underlying pre-funded warrants and up to 37,174,713 shares underlying common warrants issued in a private placement closed March 31, 2026. The company will not receive proceeds from resales but will receive cash if warrants are exercised for cash. The registration includes customary beneficial ownership blockers (4.99% or, if elected, 9.99%).
The prospectus also summarizes clinical-stage programs: WEE1 inhibitor APR-1051 (dose escalation up to 220 mg cohort; two unconfirmed partial responses reported), ATR inhibitor ATRN-119 with an RP2D of 1,100 mg once daily, and an early-stage DYRK1 program with IND-enabling studies planned in Q4 2026. Shares outstanding were 11,982,776 as of March 31, 2026.
Aprea Therapeutics, Inc. filed Pre-Effective Amendment No. 1 to its registration statement (File No. 333-293609) to furnish an updated consent of EisnerAmper LLP (Exhibit 23.2). The amendment states it does not modify any provision of the prospectus and is limited to filing the updated consent.
The amendment delays effectiveness mechanics remain unchanged and the registrant reiterates customary undertakings and exhibits, including legal opinion of DLA Piper and previously incorporated offering documents.
Aprea Therapeutics registers 12,577,714 shares for resale by private placement investors. This registration covers up to 12,577,714 shares of Common Stock consisting of 1,877,677 shares issued in the January 30, 2026 private placement, 4,411,180 shares issuable upon exercise of pre-funded warrants, and 6,288,857 shares issuable upon exercise of common warrants.
The company is not offering any shares for its own account and will not receive proceeds from resales, although it will receive proceeds from any cash exercise of warrants. The filing discloses an exercise price of $0.765 for common warrants and $0.001 for pre-funded warrants, and states the company had 11,451,118 shares outstanding as of January 30, 2026. The last reported Nasdaq sale price was $0.8179 on February 19, 2026.